The tweet was deleted by the author.
But we saved everything 🙂.
Delian Asparouhov draws attention to the notable run-rates of two major entities. Anthropic is estimated to have a run-rate of approximately $60 billion, while Keytruda, a drug that was improved in microgravity, has a run-rate near $25 billion.
Asparouhov highlights that Keytruda's significant run-rate comes from just a single drug, emphasizing the scale of both companies' financial performance.